Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Emerging Therapies | Venclexta (venetoclax) | US | Wave 2 | 2017
Venclexta (Wave 2) is the second in a multiwave series designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic lymphocytic leukemia (CLL) drug, Venclexta (Roche/AbbVie’s venetoclax). Launch Tracking Venclexta measures the impact of this novel agent on the relapsed/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. This content evaluates physicians’ current awareness and perception of Venclexta relative to other currently available therapies for relapsed/refractory CLL, current and anticipated use of Venclexta, and promotional activity of Venclexta.
Questions answered:
- What are the awareness of and familiarity with Venclexta among hematologist-oncologists?
- What are the perceived clinical advantages and disadvantages of Venclexta compared with other marketed agents used for treating relapsed/refractory CLL?
- To what extent is Venclexta currently being used by surveyed hematologist-oncologists? Where does Venclexta fit in the treatment algorithm? What reasons do nonprescribers give for not having prescribed Venclexta?
- What promotional messages are being employed by Roche/AbbVie?
Scope:
Market covered: United States.
Primary research: 75 hematologist-oncologists; qualitative interviews with 10 respondents.
Indication coverage: Relapsed/refractory CLL.
